The abstract is read at the publisher; the summary is JClub's.
Access to cancer genomics and precision oncology is profoundly unequal across and within countries, leaving millions of patients without guideline-indicated interventions each year.
- Why it matters: The Commission addresses gaps in equitable, effective, and sustainable implementation, including unequal research participation and limited evidence generation from fragmented data systems.
- What they did: It defines the global precision oncology landscape and analyzes scientific, structural, and health-system barriers, including concentration of genomic studies and clinical trials in high-income settings and predominantly European ancestry groups.
- The result: It finds clinical benefit is highly heterogeneous, with the most consistent gains limited to a few validated biomarker-treatment pairings, and proposes value-based, readiness, workforce, monitoring, and responsible data-sharing frameworks to scale more equitably.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.